Timber Creek Capital Management LLC Acquires New Position in Becton, Dickinson and Company (NYSE:BDX)

Timber Creek Capital Management LLC bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 16,113 shares of the medical instruments supplier’s stock, valued at approximately $3,691,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Becton, Dickinson and Company by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier’s stock valued at $6,067,196,000 after purchasing an additional 184,288 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in Becton, Dickinson and Company by 36.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier’s stock valued at $2,751,187,000 after buying an additional 3,219,317 shares during the last quarter. Geode Capital Management LLC boosted its stake in Becton, Dickinson and Company by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier’s stock worth $1,437,161,000 after buying an additional 66,024 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of Becton, Dickinson and Company by 15.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier’s stock valued at $1,401,126,000 after acquiring an additional 810,345 shares during the last quarter. Finally, First Eagle Investment Management LLC raised its stake in shares of Becton, Dickinson and Company by 31.4% in the 4th quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier’s stock valued at $1,004,132,000 after acquiring an additional 1,057,879 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP David Shan sold 1,166 shares of the business’s stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president directly owned 4,575 shares in the company, valued at approximately $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 479 shares of the stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at $964,107.36. This represents a 8.93% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX opened at $176.16 on Friday. The business’s 50-day simple moving average is $174.52 and its 200 day simple moving average is $208.14. The company has a market cap of $50.49 billion, a P/E ratio of 33.62, a PEG ratio of 1.34 and a beta of 0.25. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.64 and a current ratio of 1.13. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping analysts’ consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to analysts’ expectations of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the previous year, the company posted $3.17 earnings per share. On average, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 30th. Investors of record on Monday, June 9th were issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.36%. The ex-dividend date was Monday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 79.39%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on BDX. Stifel Nicolaus dropped their target price on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Wells Fargo & Company cut Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a research note on Thursday, May 1st. Bank of America lowered Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 target price on the stock. in a research note on Thursday, May 1st. Piper Sandler downgraded Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $260.00 to $185.00 in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 price target on the stock. in a research note on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $219.22.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.